Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, and Cancer Treatment and Pharmacology.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with <scp>light chain (AL)</scp> amyloidosis and high bone marrow plasma cell infiltrate
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling